- Home
- NFBK vs ARCT Comparison
NFBK vs ARCT Comparison
Compare NFBK & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NFBK
- ARCT
- Stock Information
- Founded
- NFBK 1887
- ARCT 2013
- Country
- NFBK United States
- ARCT United States
- Employees
- NFBK N/A
- ARCT N/A
- Industry
- NFBK Major Banks
- ARCT Biotechnology: Pharmaceutical Preparations
- Sector
- NFBK Finance
- ARCT Health Care
- Exchange
- NFBK Nasdaq
- ARCT Nasdaq
- Market Cap
- NFBK 559.9M
- ARCT 602.7M
- IPO Year
- NFBK 2007
- ARCT N/A
- Fundamental
- Price
- NFBK $12.77
- ARCT $15.80
- Analyst Decision
- NFBK Hold
- ARCT Strong Buy
- Analyst Count
- NFBK 2
- ARCT 7
- Target Price
- NFBK $13.63
- ARCT $65.00
- AVG Volume (30 Days)
- NFBK 137.5K
- ARCT 380.6K
- Earning Date
- NFBK 01-22-2025
- ARCT 11-07-2024
- Dividend Yield
- NFBK 4.05%
- ARCT N/A
- EPS Growth
- NFBK N/A
- ARCT N/A
- EPS
- NFBK 0.64
- ARCT N/A
- Revenue
- NFBK $124,553,000.00
- ARCT $160,399,000.00
- Revenue This Year
- NFBK N/A
- ARCT $6.91
- Revenue Next Year
- NFBK $14.71
- ARCT $5.24
- P/E Ratio
- NFBK $20.08
- ARCT N/A
- Revenue Growth
- NFBK N/A
- ARCT N/A
- 52 Week Low
- NFBK $6.98
- ARCT $14.93
- 52 Week High
- NFBK $14.39
- ARCT $45.00
- Technical
- Relative Strength Index (RSI)
- NFBK 45.94
- ARCT 37.77
- Support Level
- NFBK $12.72
- ARCT $15.55
- Resistance Level
- NFBK $13.26
- ARCT $20.92
- Average True Range (ATR)
- NFBK 0.42
- ARCT 1.11
- MACD
- NFBK -0.09
- ARCT -0.17
- Stochastic Oscillator
- NFBK 17.27
- ARCT 4.56
About NFBK Northfield Bancorp Inc. (Delaware)
Northfield Bancorp Inc is the holding company for Northfield Bank. Its subsidiary provides banking services to individuals and corporate customers in Richmond and Kings Counties in New York, and Hunterdon, Mercer, Union and Middlesex counties in New Jersey. The bank attracts deposits and offers credit and other banking services.
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the research and development segment of medical applications for nucleic acid-focused technology. The company's product pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU and LUNAR-COV19.